Loading clinical trials...

Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer | Clinical Trials | Clareo Health

COMPLETEDNA

Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer

Pilot Study of Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer Patients Requiring Treatment of the Internal Mammary Lymph Nodes

NCT01127373•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

This study is being performed to understand the safety of a new radiation treatment called "Multi-Beam Intensity Modulated Radiation Therapy" ( IMRT). Currently, the standard way of giving radiation is with "simplified" IMRT, which uses only 2 beams of radiation. "Multi-beam" IMRT works by using 6-12 small radiation beams to give a more "tailored" or "customized" radiation dose to the breast, chest wall, and the lymph nodes. At the same time, multi-beam IMRT may allow the dose to the heart, lungs, and nearby tissue to be lowered, especially when the internal mammary lymph nodes need to be targeted by radiation.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Female gender
•Age ≥18 years
•An invasive primary breast cancer of any histology arising from breast parenchyma
•Patient must be status post mastectomy or partial mastectomy with an assessment of axillary nodes via sentinel lymph node biopsy and/or axillary lymph node dissection
•Pathologic confirmation of metastatic disease in at least one regional lymph node. Regional lymph nodes are defined as the ipsilateral axillary lymph nodes, ipsilateral supraclavicular lymph nodes, and ipsilateral internal mammary lymph nodes. Thus, any T stage is allowed as long as the N stage is ≥1 and M stage is 0.
•Patient signed study-specific consent form.

Exclusion Criteria

•Patients with distant metastasis.
•Patients who are pregnant or breastfeeding.
•Patients with psychiatric or addictive disorders that would preclude obtaining informed consent.
•Time between initial diagnosis of breast cancer and start of radiation therapy exceeds 13 months.
•Estimated life expectancy judged to be less than one year by patient's treating radiation oncologist.
•Prior radiation therapy to the ipsilateral or contralateral breast or thorax.
•Primary breast cancer is a lymphoma or sarcoma histology.
•Patients with a history of non-skin malignancy \<5 years prior to the diagnosis of breast cancer.
•Patients requiring radiation to the bilateral breasts.

Locations (7)

Memorial Sloan Kettering Basking Ridge (Follow Up Only)

Basking Ridge, New Jersey, United States

Memoral Sloan Kettering Monmouth (Follow Up Only)

Middletown, New Jersey, United States

Memorial Sloan Kettering Commack (Follow Up Only)

Commack, New York, United States

Memorial Sloan Kettering Westchester (Follow Up Only)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Rockville Centre (Follow Up Only)

Rockville Centre, New York, United States

Memorial Sloan Kettering Nassau (Follow Up Only)

Uniondale, New York, United States

Key Dates

Start Date

May 11, 2010

Primary Completion Date

October 2, 2019

Completion Date

October 2, 2019

Last Updated

April 20, 2021

Enrollment

116

ACTUAL participants

Conditions

Breast Cancer

Interventions

Multi-Beam Intensity-Modulated Radiation Therapy

RADIATION

BreastQ questionnaire-

BEHAVIORAL

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 20, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer